These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20547020)

  • 1. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
    Grassetto G; Fornasiero A; Otello D; Bonciarelli G; Rossi E; Nashimben O; Minicozzi AM; Crepaldi G; Pasini F; Facci E; Mandoliti G; Marzola MC; Al-Nahhas A; Rubello D
    Eur J Radiol; 2011 Dec; 80(3):828-33. PubMed ID: 20547020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
    Xing Y; Zhao JH; Wang TS; Qiao WL; Che WJ
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
    Kruse V; Van de Wiele C; Borms M; Maes A; Pottel H; Sathekge M; Cocquyt V
    Nuklearmedizin; 2014 Aug; 53(4):131-8. PubMed ID: 25100557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers.
    Haug AR; Schmidt GP; Klingenstein A; Heinemann V; Stieber P; Priebe M; la Fougère C; Becker C; Hahn K; Tiling R
    J Comput Assist Tomogr; 2007; 31(4):629-34. PubMed ID: 17882045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET-CT in the management of primary breast lymphoma.
    Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
    Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
    Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
    Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
    Zhao TT; Li JG; Li YM
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
    Groheux D; Moretti JL; Baillet G; Espie M; Giacchetti S; Hindie E; Hennequin C; Vilcoq JR; Cuvier C; Toubert ME; Filmont JE; Sarandi F; Misset JL
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):695-704. PubMed ID: 18436392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT.
    Evangelista L; Panunzio A; Cervino AR; Vinante L; Al-Nahhas A; Rubello D; Muzzio PC; Polverosi R
    J Med Imaging Radiat Oncol; 2012 Aug; 56(4):417-24. PubMed ID: 22883649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fever of unknown origin: the role of 18F-FDG PET/CT.
    Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
    J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.